Full text is available at the source.
Abstract
A systematic review and meta-analysis will evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonists in diabetic cardiomyopathy.
- Diabetic cardiomyopathy is a significant factor in heart failure and mortality among diabetic patients.
- Existing treatment options primarily focus on blood sugar levels and symptom management, with few specific therapies for DCM.
- Glucagon-like peptide-1 receptor agonists may offer cardioprotective benefits beyond just lowering glucose levels.
- The effectiveness and safety of GLP-1 receptor agonists in treating diabetic cardiomyopathy are currently uncertain.
Simplified